Safety and efficacy of tegoprazan in patients treated with dual antiplatelet therapy after coronary stenting for acute myocardial infarction
Abstract
This study compared the efficacy and safety of tegoprazan versus proton-pump inhibitors (PPIs) for gastrointestinal (GI) protection in patients receiving dual antiplatelet therapy (DAPT) after undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). Using a Korean Nationwide database (March 2019 to September 2022), 21,276 patients treated with tegoprazan (n = 2,075) or PPIs (n = 19,201) in combination with DAPT after PCI for AMI were analyzed. The primary efficacy endpoint was GI bleeding at 1 year, and the primary safety endpoint was major adverse cardiac and cerebrovascular events (MACCE), defined as a composite of myocardial infarction or stroke. In the crude cohort, tegoprazan was associated with a lower risk of GI bleeding and major bleeding with similar MACCEs rates at 1 year compared to PPIs. After propensity-score matching, tegoprazan was consistently associated with lower risks of GI bleeding (hazard ratio [HR] 0.72, 95% confidence interval [CI] 0.54-0.98, P = 0.04) and major bleeding (HR 0.69, 95% CI 0.49-0.98, P = 0.04), without increasing the risk of MACCEs (HR 0.86, 95% CI 0.59-1.26, P = 0.45) at 1 year. In patients with AMI treated with DAPT, tegoprazan was associated with a significantly lower GI bleeding risk versus PPIs, without increasing ischemic events.
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 21,276 participants or records.
Read the paper
Related studies
- Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
- Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study
- Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
- Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study
- Ethnic and socioeconomic differences in SARS-CoV-2 infection: prospective cohort study using UK Biobank
- Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.